Newly appointed Zealand Pharma CEO says commercial organization was too expensive
Going forward, Zealand Pharma’s revenue will come from strategic partnerships, which is why the company is significantly reducing its commercial unit and workforce in the US. It’s too expensive to have a commercial department with few products on the market, says Adam Steensberg, the company’s new CEO.
by christopher due karlsson, translated by daniel pedersen
Having spent a lot of funds the past few years on building up an commercial organization in the US, biotech company Zealand Pharma has decided to change lanes completely.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma appoints head of R&D as CEO
For subscribers
